Acetylcholinesterase inhibitors: a patent review (2008 - present)
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Acetylcholine metabolism MeSH
- Acetylcholinesterase metabolism MeSH
- Alzheimer Disease drug therapy enzymology MeSH
- Cholinesterase Inhibitors adverse effects chemistry pharmacology MeSH
- Chemistry, Pharmaceutical MeSH
- Humans MeSH
- Molecular Structure MeSH
- Myasthenia Gravis drug therapy enzymology MeSH
- Patents as Topic MeSH
- Drug Design MeSH
- Structure-Activity Relationship MeSH
- Legislation, Drug MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Acetylcholine MeSH
- Acetylcholinesterase MeSH
- Cholinesterase Inhibitors MeSH
INTRODUCTION: Both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are present in the body in large amounts. AChE is an important part of the cholinergic nervous system taking place in the central and peripheral nervous system. AChE is a target of several toxins such as insecticide carbofuran, nerve agents, sarin, soman, tabun and VX. Beside toxins, drugs for treatment of Alzheimer's disease and myasthenia gravis, such as galantamine, donepezil, rivastigmine, tacrine, huperzine, pyridostigmine and neostigmine, are known. AREAS COVERED: The review gives an overview of the importance of the cholinergic nervous system, the biochemistry of AChE and the role of AChE inhibitors. Current efforts to introduce potent drugs for Alzheimer's disease therapy and reduce toxicity, while keeping the maximal pharmacological effect, are also discussed. EXPERT OPINION: The current research effort into AChE inhibitors can be divided into two categories. First, new toxins useful for agricultural purposes and second, novel drugs that need to be prepared, although there is less interest in the new toxins. The research for drugs for Alzheimer's disease needs to focus on inhibitors that reduce the deposition of amyloid plaques, but do not initiate AChE expression.
References provided by Crossref.org
Acetylcholinesterase: The "Hub" for Neurodegenerative Diseases and Chemical Weapons Convention
Biosensors and Bioassays Based on Lipases, Principles and Applications, a Review
Inhibition of Acetylcholinesterase and Butyrylcholinesterase by a Plant Secondary Metabolite Boldine
Anti-Parkinson Drug Biperiden Inhibits Enzyme Acetylcholinesterase
Postponed effect of neostigmine on oxidative homeostasis
Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity
Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase
Galantamine effect on tularemia pathogenesis in a BALB/c mouse model
